Patents by Inventor Katsuki TAKASHIMA

Katsuki TAKASHIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124430
    Abstract: Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 18, 2024
    Applicant: KINKI UNIVERSITY
    Inventors: Shozo NISHIDA, Masanobu TSUBAKI, Tomoya TAKEDA, Genzoh TANABE, Katsuki TAKASHIMA
  • Publication number: 20240115589
    Abstract: [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Solution to Problem] Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin.
    Type: Application
    Filed: February 14, 2022
    Publication date: April 11, 2024
    Applicant: KINKI UNIVERSITY
    Inventors: Shozo NISHIDA, Masanobu TSUBAKI, Tomoya TAKEDA, Genzoh TANABE, Katsuki TAKASHIMA, Toshio MORIKAWA